The FDA has granted fast track designation to the SGLT2 inhibitor dapagliflozin for reducing the risk for cardiovascular death or worsening heart failure among adults with heart failure with reduced or preserved ejection fraction, according to a press release from AstraZeneca.
The FDA’s decision marks the second fast track designation for the diabetes drug in 4 weeks. In August, the agency granted fast track designation to dapagliflozin (Farxiga) for treatment of patients with or without diabetes who have chronic kidney disease to delay progression of renal failure and to prevent CV and
Anupam Ghose, a physician by training, was diagnosed with Type 2 Diabetes Mellitus (T2DM) in 2017. After the diagnosis of T2DM, he followed a low carbohydrate high fat diet and reversed his T2DM within a year. Now he has one main goal in life. Yes, it is to make people understand that the conventional method of treating T2DM is not beneficial. The best way to reverse and fight T2DM is through diet and lifestyle modification. He decided to help people suffering from T2DM in their new journey by offering consultations and working together with them in order to achieve a T2DM free life.